Johnson & Johnson (NYSE:JNJ) Earns Buy Rating from Guggenheim

Johnson & Johnson (NYSE:JNJ)‘s stock had its “buy” rating restated by equities research analysts at Guggenheim in a note issued to investors on Wednesday, MarketBeat.com reports. They presently have a $287.00 price objective on the stock. Guggenheim’s price objective indicates a potential upside of 11.13% from the company’s current price.

Other equities analysts have also recently issued reports about the stock. HSBC raised their price objective on shares of Johnson & Johnson from $290.00 to $320.00 and gave the company a “buy” rating in a research note on Thursday, September 10th. Johnson Rice reaffirmed a “buy” rating on shares of Johnson & Johnson in a research note on Monday, August 3rd. Wells Fargo & Company raised their price objective on shares of Johnson & Johnson from $272.00 to $282.00 and gave the company an “overweight” rating in a research note on Monday, August 3rd. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $282.00 price objective on shares of Johnson & Johnson in a research note on Thursday, July 16th. Finally, TD Cowen raised their price objective on shares of Johnson & Johnson from $250.00 to $300.00 and gave the company a “buy” rating in a research note on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $276.22.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock traded up $3.47 during midday trading on Wednesday, reaching $258.25. The company had a trading volume of 5,394,094 shares, compared to its average volume of 7,981,786. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44. The company has a market capitalization of $622.35 billion, a price-to-earnings ratio of 29.92, a price-to-earnings-growth ratio of 2.48 and a beta of 0.21. The stock has a fifty day simple moving average of $265.71 and a 200 day simple moving average of $248.78. Johnson & Johnson has a 1-year low of $184.66 and a 1-year high of $281.07.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, beating analysts’ consensus estimates of $2.84 by $0.06. The business had revenue of $25.31 billion during the quarter, compared to analyst estimates of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. Johnson & Johnson’s revenue for the quarter was up 6.6% compared to the same quarter last year. During the same quarter last year, the business posted $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, equities research analysts forecast that Johnson & Johnson will post 11.54 earnings per share for the current year.

Insider Activity

In other news, EVP Elizabeth Forminard sold 15,918 shares of Johnson & Johnson stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the transaction, the executive vice president directly owned 16,994 shares of the company’s stock, valued at $4,367,458. This trade represents a 48.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Jennifer Taubert sold 15,000 shares of Johnson & Johnson stock in a transaction on Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the transaction, the executive vice president directly owned 194,451 shares in the company, valued at approximately $51,210,615.36. This represents a 7.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 87,569 shares of company stock valued at $23,064,544. 0.16% of the stock is owned by company insiders.

Hedge Funds Weigh In On Johnson & Johnson

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Auto Owners Insurance Co boosted its position in shares of Johnson & Johnson by 22,225.6% during the fourth quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company’s stock worth $1,436,633,000 after purchasing an additional 69,108,368 shares in the last quarter. Wellington Management Group LLP boosted its position in shares of Johnson & Johnson by 12.5% during the second quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company’s stock worth $5,736,851,000 after purchasing an additional 2,513,321 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Johnson & Johnson by 8.7% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 17,275,937 shares of the company’s stock worth $3,575,255,000 after purchasing an additional 1,376,828 shares in the last quarter. Deutsche Bank AG raised its holdings in shares of Johnson & Johnson by 8.5% during the second quarter. Deutsche Bank AG now owns 15,661,323 shares of the company’s stock worth $3,977,506,000 after acquiring an additional 1,225,676 shares during the period. Finally, Amundi raised its holdings in shares of Johnson & Johnson by 17.5% during the first quarter. Amundi now owns 13,406,820 shares of the company’s stock worth $3,277,163,000 after acquiring an additional 2,001,139 shares during the period. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Analyst support remains strong. Guggenheim reaffirmed its “Buy” rating and set a $287 price target, implying roughly 11% upside from the referenced price. RBC Capital also maintained its “Buy” rating. RBC Capital Keeps Their Buy Rating on Johnson & Johnson
• Positive Sentiment: Investors are increasingly viewing JNJ as a growth story. Recent coverage highlighted second-quarter revenue growth of 6.6%, adjusted EPS growth of 4.7% and an increase in full-year 2026 guidance. This contrasts with Pfizer, whose lower valuation reflects expectations for declining earnings, helping explain why JNJ commands a much higher earnings multiple. Johnson & Johnson Is Becoming a Growth Stock
• Positive Sentiment: Pipeline progress adds longer-term upside. JNJ’s Tecvayli-Talvey combination produced substantial reductions in progression and mortality risk in a Phase 3 multiple-myeloma study. Separately, two-year data for oral psoriasis treatment ICOTYDE showed durable skin clearance and consistent safety, supporting its commercial potential. 2026 Cancer Treatment Advances ICOTYDE Long-Term Psoriasis Data
• Neutral Sentiment: A pricing agreement may reduce an overhang before earnings. Coverage said a pricing pact has eased investor concerns ahead of the company’s next results, though the precise financial impact and durability of the agreement remain important items to monitor. Johnson & Johnson Pricing Pact Eases Overhang
• Negative Sentiment: Risks temper the bullish case. Analysts and investors continue to assess biosimilar competition, a slower MedTech recovery, the coming pharmaceutical patent cliff and ongoing talc litigation. JNJ’s premium valuation leaves less room for execution or earnings disappointments. Johnson & Johnson Dividend Royalty Status

About Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.